Genmab's Humax-CD20 cancer antibody shows promising results in primate study
HuMax-CD20 depleted B-cells, the target in non-Hodgkins lymphoma, for longer than rituximab
30-Jun-2003 -
Summary: Genmab's HuMax-CD20 antibody effective in depleting B-cells, the target for treating non-Hodgkin's lymphoma, in primate study.
Genmab A/S announced today that HuMax-CD20 was effective in depleting B-cells, the target for treating non-Hodgkin's lymphoma, in both blood and lymph nodes in ...
clinical trials
Cyprus
Genmab
+4